| Name | Title | Contact Details |
|---|
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Healthcare Integrated Technologies, Inc. is focused on developing effective, non-intrusive, resident monitoring technologies for senior living communities. Healthcare Integrated Technologies is headquartered in Knoxville, Tennessee.
Brown Physicians, Incorporated (BPI) is a community-based not-for-profit multi-specialty practice group founded and led by faculty affiliated with The Warren Alpert Medical School of Brown University. Our mission is to provide outstanding patient care, exceptional medical education, and groundbreaking advances in research to promote better health for the people of Rhode Island and its surrounding communities. BPI is composed of six foundations, which include Brown Dermatology, Brown Emergency Medicine, Brown Medicine, Brown Neurology, Brown Urology, and University Surgical Associates.
The employees of SynergEyes are committed to provide the highest quality, technologically advanced hybrid contact lenses that address a wide spectrum of vision conditions, while continuously meeting the needs of today's Practitioner and Patient.
Rainy Lake Medical Center is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in International Falls, MN. To find more information about Rainy Lake Medical Center, please visit www.rainylakemedical.com